Inventor · disambiguated record
Petra Rueger
Also filed as: RUEGER PETRA
22 granted patents·19 pending applications·164 citations·filing 1999–2025
95Inventor score
Top patents by PatentIndex Score
41 records- 0195US10941205B2Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2018·Granted Mar 9, 2021·10 cites·13 claims
- 0295US7462639B2Aminopyrazole derivativesHOFFMANN LA ROCHE·Filed 2006·Granted Dec 9, 2008·46 cites·17 claims
- 0393US10011644B2Method for producing soluble FcR as Fc-fusion with inert immunoglobulin Fc-region and uses thereofHOFFMANN LA ROCHE·Filed 2015·Granted Jul 3, 2018·9 cites·3 claims
- 0491US11603411B2Bispecific anti-human CD20/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2018·Granted Mar 14, 2023·9 cites·5 claims
- 0590US12030952B2Bispecific anti-human CD20/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2022·Granted Jul 9, 2024·1 cites·10 claims
- 0689US10364292B2Monovalent blood brain barrier shuttle modulesHOFFMANN LA ROCHE·Filed 2016·Granted Jul 30, 2019·10 cites·10 claims
- 0788US11787868B2Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2020·Granted Oct 17, 2023·1 cites·5 claims
- 0885US2025297025A1Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 0984US6627439B2Antibodies against SEMP1(p23)HOFFMANN LA ROCHE·Filed 2001·Granted Sep 30, 2003·26 cites·6 claims
- 1083US7655651B2Amide derivatives of 3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agentsHOFFMANN LA ROCHE·Filed 2005·Granted Feb 2, 2010·9 cites·8 claims
- 1183US7494993B2Amide derivatives of 7-amino-3-phenyl-dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agentsHOFFMANN LA ROCHE·Filed 2005·Granted Feb 24, 2009·8 cites·15 claims
- 1283US2023365702A1Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1382US11780919B2Bispecific antigen binding molecules targeting OX40 and FAPHOFFMANN LA ROCHE·Filed 2021·Granted Oct 10, 2023·1 cites·24 claims
- 1482US7226923B2Phthalazinone derivativesHOFFMANN LA ROCHE·Filed 2005·Granted Jun 5, 2007·8 cites·49 claims
- 1582US2024317879A1Bispecific anti-human cd20/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 1681US12358997B1Bispecific anti-human A-beta/anti-human transferrin receptor antibodiesHOFFMANN LA ROCHE·Filed 2025·Granted Jul 15, 2025·0 cites·2 claims
- 1777US2024124519A1Fc-receptor based affinity chromatographyHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1874US10093714B1Method for producing soluble FcR as Fc-fusion with inert immunoglobulin Fc-region and uses thereofHOFFMANN LA ROCHE·Filed 2018·Granted Oct 9, 2018·1 cites·5 claims
- 1973US11945839B2Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatographyHOFFMANN LA ROCHE·Filed 2018·Granted Apr 2, 2024·1 cites·17 claims
- 2073US2024117049A1Bispecific antigen binding molecules targeting ox40 and fapHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 2172US6818623B2Active hedgehog protein conjugateCURIS INC·Filed 2002·Granted Nov 16, 2004·5 cites·14 claims
- 2269US7153836B2Active hedgehog protein conjugateCURIS INC·Filed 2004·Granted Dec 26, 2006·3 cites·17 claims
- 2368US2025051429A1Anti-a-beta protein antibodies, methods and uses thereofHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 2466US2025163173A1Monovalent blood brain barrier shuttle modulesHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 2565US11814409B2Fc-receptor based affinity chromatographyHOFFMANN LA ROCHE·Filed 2019·Granted Nov 14, 2023·0 cites·16 claims
- 2665US6468978B1Active hedgehog protein conjugateCURIS INC·Filed 1999·Granted Oct 22, 2002·16 cites·15 claims
- 2765US2020216554A1Bispecific anti-human cd20/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 2863US11440942B2Complement factor based affinity chromatographyHOFFMANN LA ROCHE·Filed 2019·Granted Sep 13, 2022·0 cites·12 claims
- 2959US2005118169A1Antibodies against interleukin-1 receptor and uses thereofFiled 2004·Application pending·0 cites
- 3057US2009191187A1Antibodies against interleukin-1 receptor and uses thereofBARTKE ILSE·Filed 2009·Application pending·0 cites
- 3156US2015018241A1Fc-receptor based affinity chromatographyHOFFMANN LA ROCHE·Filed 2013·Application pending·0 cites
- 3256US2020071413A1Monovalent blood brain barrier shuttle modulesHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 3354US2007191274A1Active hedgehog protein conjugateESSWEIN ANGELIKA·Filed 2006·Application pending·0 cites
- 3453US7393936B2Method for the recombinant production and purification of protein kinasesHOFFMANN LA ROCHE·Filed 2004·Granted Jul 1, 2008·0 cites·12 claims
- 3551US7285569B2Tricycles, their manufacture and use as pharmaceutical agentsHOFFMANN LA ROCHE·Filed 2005·Granted Oct 23, 2007·0 cites·11 claims
- 3646US2009221599A1Phthalazinone pyrazole derivatives, their manufacture and use as pharmaceutical agentsBOYD EDWARD·Filed 2007·Application pending·0 cites
- 3744US2009143375A1Tricyclic Lactam Derivatives, Their Manufacture and Use as Pharmaceutical AgentsHOFFMANN LA ROCHE·Filed 2006·Application pending·0 cites
- 3842US2009227578A1Azabenzimidazole Derivatives, Their Manufacture and Use as Anti-Cancer AgentsENGH RICHARD·Filed 2006·Application pending·0 cites
- 3938US2009291968A1Substituted indazole derivatives, their manufacture and use as pharmaceutical agentsGEORGES GUY·Filed 2007·Application pending·0 cites
- 4038US2006142247A1Tricyclic heterocyclesGEORGES GUY·Filed 2005·Application pending·0 cites
- 4137US2006235013A1Tricyclic azole derivativesGEORGES GUY·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Petra Rueger files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →